Zhejiang Medicine Co., Ltd.

Equities

600216

CNE0000010J2

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
9.53 CNY +0.42% Intraday chart for Zhejiang Medicine Co., Ltd. +2.47% -11.18%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Medicine Wins Nod to Trial Digestive Acid Drug MT
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Medicine Wins Nod to Trial Anti-Tumor Drug MT
Zhejiang Medicine’s South Korean Unit Clears Good Manufacturing Practice Inspection MT
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Citic Securities says global financial market fluctuations hurt business RE
Zhejiang Medicine to Market Antibiotic in the US After Getting FDA Nod; Shares Jump 3% MT
Zhejiang Medicine Co., Ltd.(SHSE:600216) dropped from Shanghai Stock Exchange Health Care Sector Index CI
Zhejiang Medicine Unit Gets Clinical Trial Approval For Anti-Biliary Tract Cancer Drug MT
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Brokerage CLSA vice-chairman Charles Lin resigns RE
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Medicine Co., Ltd.(SHSE:600216) added to Shanghai Stock Exchange Health Care Sector Index CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
TaiGen Biopharmaceuticals Turns to Profit in 2021 MT
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Zhejiang Medicine Co., Ltd.(SHSE:600216) dropped from Shanghai Stock Exchange Health Care Sector Index CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Zhejiang Health Creation Bio-Technology Co., Ltd. announced that it expects to receive funding from Zhejiang Medicine Co., Ltd. CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Chart Zhejiang Medicine Co., Ltd.
More charts
Zhejiang Medicine Co., Ltd. is a China-based company, principally engaged in the manufacture and distribution of drugs and nourishments. The Company mainly provides nourishments for animals and human, health care products, and chemicals and chemical raw materials, among others. The Company's products include synthetic vitamin E, natural vitamin E soft capsules, Beta carotene, vancomycin hydrochloride for injection and teicoplanin for injection, among others. The Company distributes its products within domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.53 CNY
Average target price
13 CNY
Spread / Average Target
+36.41%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 600216 Stock
  4. News Zhejiang Medicine Co., Ltd.
  5. Zhejiang Medicine Wins Nod to Trial Anti-Tumor Drug